If you’ve ever watched the Star Trek TV show, or any of the franchise’s movies, you’ve probably noticed that spaceship medicine is different from what we’re accustomed to. Instead of a physical exam, on the Starship Enterprise, the doctor points a blinking device at the patient and arrives at an instant diagnosis of any health issue.
Could that ever happen in real life? It could—and has!
Chip maker and tech company Qualcomm has been, since 2012, sponsoring a Tricorder XPrize Competition, offering $2.5 million to the company that can diagnose, with remote sensors, 13 health conditions: anemia, urinary tract infection, diabetes, atrial fibrillation, stroke, sleep apnea, tuberculosis, chronic obstructive pulmonary disease, pneumonia, otitis, leukocytosis and hepatitis. The winning device would also be able to assess a patient’s vital signs, like blood pressure, respiratory rate and temperature through wireless sensors, imaging technologies and non-invasive replacements of laboratory equipment. (A second prize of $1 million was also part of the competition.)
The social benefits of such a device are obvious: a huge percentage of the country’s health care spending goes toward expensive testing procedures, and fast, accurate diagnoses are also the key to fast, successful treatments. Imagine a world where medical costs—including the costs of Medicare and health insurance premiums—are reduced by 30%, and people can buy a device that allows them to diagnose their own ailments.
In all, 312 teams entered the competition, including government-sponsored groups and medical corporations. The recently-announced winner: Final Frontier Medical Devices, founded by an emergency medicine doctor named Basil Harris.
Instead of a hand-held device, the winning tricorder—called DxtER, is roughly the size of a shoe box, containing several individual diagnostic devices and sensors that patients can apply to themselves. The devices, linked to an Apple iPad, will go beyond the specifications and diagnose 34 different medical conditions, in addition to the aforementioned vital signs. The next round of the competition will look for a way to create a commercial version.
Stay Diversified, Stay the Course!
Empyrion Wealth Management (“Empyrion”) is an investment advisor registered with the U.S. Securities and Exchange Commission under the Investment Advisers Act of 1940. Information pertaining to Empyrion’s advisory operations, services and fees is set forth in Empyrion’s current Form ADV Part 2A brochure, copies of which are available upon request at no cost or at www.adviserinfo.sec.gov. The views expressed by the author are the author’s alone and do not necessarily represent the views of Empyrion. The information contained in any third-party resource cited herein is not owned or controlled by Empyrion, and Empyrion does not guarantee the accuracy or reliability of any information that may be found in such resources. Links to any third-party resource are provided as a courtesy for reference only and are not intended to be, and do not act as, an endorsement by Empyrion of the third party or any of its content. The standard information provided in this blog is for general purposes only and should not be construed as, or used as a substitute for, financial, investment or other professional advice. If you have questions regarding your financial situation, you should consult your financial planner or investment advisor.